What should I expect from my first PT-141 dose?
Three things show up most in trials: facial flushing in roughly 1 in 5 people, headache in roughly 2 in 5, and nausea in roughly 1 in 4. Reported effects tend to start within 30 to 60 minutes and ease over the next few hours. The dose, the timing, and whether it fits your health history are decisions for you and your provider, not numbers the app sets for you. If you get the green light, the reconstitution calculator can turn the dose you and your provider land on into syringe units. Bring any heart or blood pressure history to that conversation, since the prescribing label carries a boxed warning around uncontrolled hypertension.
- Bremelanotide (PT-141) is approved in the US for premenopausal women with HSDD under the brand Vyleesi
- Common side effects in the RECONNECT trials: nausea (~40%), flushing (~20%), headache (~11%), injection site reactions
- Onset 30-60 minutes after subQ injection, peak 1-2 hours, total duration 2-4 hours
- Transient blood pressure increase of 6 mmHg systolic / 3 mmHg diastolic is documented in the prescribing label
- Boxed warning on the prescribing label restricts use in uncontrolled hypertension and known cardiovascular disease
Your guided peptide companion.
PRTCL walks beginners through their first peptide with confidence - guided reconstitution, syringe unit math from your own numbers, vial tracking, and answers to questions like this one. Built for first-timers, useful for everyone.
- · Guided walkthrough for your first dose
- · Your vial and your dose, converted into syringe units
- · Vial inventory and dose log tracking
- · A library where every claim cites its source
Free to start.